首页> 美国卫生研究院文献>Oncoimmunology >Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

【2h】

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

机译：EML4-ALK融合蛋白对PD-L1的上调介导ALK阳性NSCLC的免疫逃逸：对ALK-TKI敏感和耐药的NSCLC患者可选的抗PD-1 / PD-L1免疫疗法的意义

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Oncoimmunology
作者
Shaodong Hong; Nan Chen; Wenfeng Fang; Jianhua Zhan; Qing Liu; Shiyang Kang; Xiaobo He; Lin Liu; Ting Zhou; Jiaxing Huang; Ying Chen; Tao Qin; Yaxiong Zhang; Yuxiang Ma; Yunpeng Yang; Yuanyuan Zhao; Yan Huang; Li Zhang;
展开▼
作者单位

展开▼
年(卷),期 2016(5),3
年度 2016
页码 e1094598
总页数 12
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients [J] . Hong Shaodong, Chen Nan, Fang Wenfeng, Oncoimmunology. . 2016,第3期

机译：EML4-ALK融合蛋白对PD-L1的上调介导ALK阳性NSCLC的免疫逃逸：对ALK-TKIs敏感和耐药NSCLC患者的可选抗PD-1 / PD-L1免疫疗法的意义
2. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J] . Chen Nan, Fang Wenfeng, Zhan Jianhua, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第6期

机译：EGFR激活对PD-L1的上调介导了EGFR驱动的NSCLC的免疫逃逸，提示对EGFR突变的NSCLC患者进行选择性免疫靶向治疗
3. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC [J] . Yayi He, Sangtian Liu, Jane Mattei, Drug Design, Development and Therapy . 2018,第4期

机译：抗KIR单克隆抗体与抗PD-1 / PD-L1单克隆抗体的组合可能是克服NSCLC肿瘤免疫逃逸的关键突破
4. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC [O] . Yayi He, Sangtian Liu, Jane Mattei, 2018

机译：抗KIR单克隆抗体与抗PD-1 / PD-L1单克隆抗体的组合可能是克服NSCLC肿瘤免疫逃逸的关键突破
5. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [O] . Chen Nan, Fang Wenfeng, Zhan Jianhua, 2015

机译：EGFR激活对PD-L1的上调介导了EGFR驱动的NSCLC的免疫逃逸：EGFR突变的NSCLC患者的选择性免疫靶向治疗的意义

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

著录项

相似文献

相关主题

期刊订阅